Sophiris Bio (NASDAQ:SPHS) Upgraded at ValuEngine

ValuEngine upgraded shares of Sophiris Bio (NASDAQ:SPHS) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, ValuEngine reports.

Separately, Maxim Group set a $6.00 target price on Sophiris Bio and gave the stock a buy rating in a research report on Wednesday, June 19th.

Shares of NASDAQ SPHS remained flat at $$0.98 during midday trading on Thursday. The stock had a trading volume of 116,271 shares, compared to its average volume of 118,288. Sophiris Bio has a twelve month low of $0.71 and a twelve month high of $3.49. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a 50-day simple moving average of $0.93.

Sophiris Bio (NASDAQ:SPHS) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.02. On average, research analysts expect that Sophiris Bio will post -0.36 EPS for the current fiscal year.

A hedge fund recently raised its stake in Sophiris Bio stock. Geode Capital Management LLC boosted its position in Sophiris Bio Inc (NASDAQ:SPHS) by 14.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 243,523 shares of the biopharmaceutical company’s stock after buying an additional 31,579 shares during the quarter. Geode Capital Management LLC owned approximately 0.81% of Sophiris Bio worth $202,000 at the end of the most recent quarter. Institutional investors own 8.27% of the company’s stock.

About Sophiris Bio

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Recommended Story: Why does the United States have a lingering trade deficit?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.